Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

The escalating prevalence of obesity and type 2 diabetes has spurred innovation in therapeutic solutions, and the spotlight is now on retatrutide, a new experimental drug showing remarkable weight ...

Retatrutide is a synthetic peptide, which research indicates functions as a triple agonist for type 2 diabetes and weight loss. Peptides, small chains of amino acids, have been hypothesized to ...

The new experimental weight loss drug, Retatrutide, is showing promising results. According to a study in the Annals of Internal Medicine, Retatrutide may help obese adults shed more pounds than ...

Can Lilly immunize retatrutide from compounded copies? Will the district court second guess – much less overturn – FDA’s decision to regulate this GLP-1 as a drug? Although perhaps a bit ...